|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.95 USD | -0.38% |
|
-6.58% | -22.89% |
| May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
| May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
NeuroPace, Inc. provided revenue guidance for the year 2022. For the year, the company expected total revenue of $45 million to $48 million.
| 1st Jan change | Capi. | |
|---|---|---|
| -22.89% | 229M | |
| +11.18% | 225B | |
| +15.22% | 197B | |
| +19.19% | 143B | |
| +30.89% | 111B | |
| +1.56% | 64.72B | |
| +18.48% | 54.44B | |
| +5.12% | 51.06B | |
| +10.53% | 45.03B | |
| +5.98% | 37.4B |
NEUROPACE, INC. 